Literature DB >> 18514302

Targeting angiogenesis in pancreatic cancer.

Philip A Philip1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18514302     DOI： 10.1016/S0140-6736(08)60770-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.

Authors:  Birgit Hotz; Marina V Backer; Joseph M Backer; Heinz-J Buhr; Hubert G Hotz
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

Review 2.  Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

Authors:  Jie-Er Ying; Li-Ming Zhu; Bi-Xia Liu
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

Review 3.  The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.

Authors:  Subhankar Chakraborty; Sukhwinder Kaur; Sushovan Guha; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2012-03-31

4.  Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3.

Authors:  Srinivas Reddy Boreddy; Ravi P Sahu; Sanjay K Srivastava
Journal:  PLoS One       Date:  2011-10-10       Impact factor: 3.240

5.  Combining two strategies to improve perfusion and drug delivery in solid tumors.

Authors:  Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.